Since most FSHD patients are asymptomatic in childhood/early adolescence, this raises the question of whether developing/growing muscle is better able to respond to DUX4 or factors such as oxidative stress, rendering any effects initially subclinical. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.